Open Access

A retrospective study of laryngeal squamous cell carcinoma and the significance of the PIK3CA mutation for survival

  • Authors:
    • Akinobu Kubota
    • Nobuyuki Bandoh
    • Takashi Goto
    • Michihisa Kono
    • Ryosuke Sato
    • Shiori Suzuki
    • Shota Sakaue
    • Ryuhei Takeda
    • Shuto Hayashi
    • Misaki Hayashi
    • Daisuke Araki
    • Shogo Baba
    • Yasutaka Kato
    • Miki Takahara
    • Hiroshi Nishihara
    • Hajime Kamada
  • View Affiliations

  • Published online on: July 17, 2025     https://doi.org/10.3892/mco.2025.2882
  • Article Number: 87
  • Copyright: © Kubota et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of this study was to assess clinical features, outcomes and survival in patients with laryngeal squamous cell carcinoma (LSCC) and to associate mutations in cancer‑related genes with clinical outcomes. A total of 88 patients with LSCC who underwent curative treatment between April 2008 and May 2024 at Hokuto Hospital (Obihiro, Japan) were included. Mutations in targeted regions of 160 cancer‑related genes were analyzed using next‑generation sequencing (NGS). LSCC was of glottic type in 65 patients (74%) and supraglottic type in 23 patients (26%). As initial treatment, laryngomicrosurgery, radiotherapy (RT) alone, RT with transoral administration of S‑1, concurrent chemoradiotherapy with cisplatin, and total laryngectomy were performed in 6 (7%), 48 (55%), 13 (15%), 8 (9%), and 13 (15%) patients, respectively. Of the 88 patients studied, 25 (28%) died of various causes, including LSCC in 6 (7%), carcinoma other than LSCC in 11 (13%), and other causes in 8 (9%). The 5‑year survival rates among all 88 patients with LSCC were 78.7% for overall survival (OS), 91.4% for disease‑specific survival (DSS), 77.3% for relapse‑free survival (RFS) and 67.5% for laryngectomy‑free survival (LFS). OS, DSS, RFS and LFS in patients with early stage LSCC were similar to rates reported in other studies. Actionable mutations were detected in 21 (88%) of 24 patients who underwent NGS‑based cancer panel testing. TP53 mutations were detected in 18 (75%), KMT2D in 5 (21%), PTEN in 3 (13%) and PIK3CA in 2 (8%) of these 24 patients. Multivariate Cox proportional hazard analysis revealed that PIK3CA mutation was an independent prognostic factor for RFS (P=0.011). Overall, detection of mutations in cancer‑related genes could enhance understanding of clinical outcomes in LSCC.
View Figures
View References

Related Articles

Journal Cover

October-2025
Volume 23 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kubota A, Bandoh N, Goto T, Kono M, Sato R, Suzuki S, Sakaue S, Takeda R, Hayashi S, Hayashi M, Hayashi M, et al: A retrospective study of laryngeal squamous cell carcinoma and the significance of the PIK3CA mutation for survival. Mol Clin Oncol 23: 87, 2025.
APA
Kubota, A., Bandoh, N., Goto, T., Kono, M., Sato, R., Suzuki, S. ... Kamada, H. (2025). A retrospective study of laryngeal squamous cell carcinoma and the significance of the PIK3CA mutation for survival. Molecular and Clinical Oncology, 23, 87. https://doi.org/10.3892/mco.2025.2882
MLA
Kubota, A., Bandoh, N., Goto, T., Kono, M., Sato, R., Suzuki, S., Sakaue, S., Takeda, R., Hayashi, S., Hayashi, M., Araki, D., Baba, S., Kato, Y., Takahara, M., Nishihara, H., Kamada, H."A retrospective study of laryngeal squamous cell carcinoma and the significance of the PIK3CA mutation for survival". Molecular and Clinical Oncology 23.4 (2025): 87.
Chicago
Kubota, A., Bandoh, N., Goto, T., Kono, M., Sato, R., Suzuki, S., Sakaue, S., Takeda, R., Hayashi, S., Hayashi, M., Araki, D., Baba, S., Kato, Y., Takahara, M., Nishihara, H., Kamada, H."A retrospective study of laryngeal squamous cell carcinoma and the significance of the PIK3CA mutation for survival". Molecular and Clinical Oncology 23, no. 4 (2025): 87. https://doi.org/10.3892/mco.2025.2882